1. Jakobsen, JC, Katakam, KK, Schou, A et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 2017;17:58.
2. Hieronymus, F, Lisinski, A, Näslund, J, Eriksson, E. Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective. Acta Neuropsychiatr 2017;1–7.
3. Wernicke, J, Dunlop, SR, Dornseif, BE, Zerbe, R. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23:164–168.
4. Wernicke, JF, Dunlop, SR, Dornseif, B, Bosomworth, J, Humbert, M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24:183–188.
18. Byerley, WF, Reimherr, FW, Wood, DR, Grosser, BI. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988;8:112–115.
19. Claghorn, JL, Earl, CQ, Walczak, DD et al. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996;16:113–120.
20. Cohn, J, Wilcox, C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985;46(Pt 2):26–31.
21. Coleman, CC, Cunningham, LA, Foster, VJ et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11:205–215.
22. Goldstein, DJ, Lu, Y, Detke, MJ, Wiltse, C, Mallinckrodt, C, Demitrack, MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389–399.
23. Itil, T, Shrivastava, R, Mukherjee, S, Coleman, B, Michael, S. A double‐blind placebo‐controlled study of fluvoxamine and imipramine in out‐patients with primary depression. Br J Clin Pharmacol 1983;15(Suppl. 3):433S–438S.
24. Olie, J, Gunn, K, Katz, E. A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression. Eur Psychiatry 1997;12(1):34–41.
25. Sramek, JJ, Kashkin, K, Jasinsky, O, Kardatzke, D, Kennedy, S, Cutler, NR. Placebo-controlled study of ABT-200 versus fluoxetine in the treatment of major depressive disorder. Depression 1995;3(4):199–203.
30. Kranzler, HR, Mueller, T, Cornelius, J et al. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2006;26:13–20.
31. Pettinati, HM, Oslin, DW, Kampman, KM et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010;167:668–675.
32. Ravindran, A, Teehan, M, Bakish, D et al. The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Hum Psychopharmacol 1995;10:273–281.
33. Nyth, A, Gottfries, C, Lyby, K et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138–145.
36. Kasper, S, de Swart, H, Andersen, HF. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005;13:884–891.
37. Forest Laboratories Inc: Study no. SCT-MD-01, Unpublished Data, Study report from U.S. Food and Drug Administration.
42. Forest Laboratories Inc. Scientific result summary –SCT-MD-27.
44. Rapaport, MH, Lydiard, RB, Pitts, CD et al. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2009;70:46–57.
45. Schneider, LS, Nelson, JC, Clary, CM et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003;160:1277–1285.
49. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287:1807–1814.
50. Coleman, CC, King, BR, Bolden-Watson, C et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001;23:1040–1058.
51. Feighner, JP, Boyer, W. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand 1989;80(S350):125–129.
52. Lepola, UM, Loft, H, Reines, EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo‐controlled study in depression in primary care. Int Clin Psychopharmacol 2003;18:211–217.
53. Rapaport, MH, Schneider, LS, Dunner, DL, Davies, JT, Pitts, CD. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry 2003;64:1065–1074.
54. Rickels, K, Amsterdam, J, Clary, C, Fox, I, Schweizer, E, Weise, C. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. J Clin Psychiatry. 1992;53(Suppl):30–32.
56. Sweeting, MJ, Sutton, AJ, Lambert, PC. What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Stat Med 2004;23:1351–1375.
57. Kuss, O. Statistical methods for meta‐analyses including information from studies without any events—add nothing to nothing and succeed nevertheless. Stat Med 2015;34:1097–1116.
58. Sharma, T, Gøtzsche, PC, Kuss, O. The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials. J Clin Epidemiol 2017;91:129–136.
59. Jakobsen, JC, Lindschou, J, Hellmuth, S, Schou, A, Krogh, J, Gluud, C. The effects of selective serotonin reuptake inhibitors versus no intervention, placebo, or ‘active’ placebo in patients with major depressive disorder. A systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. PROSPERO, 2013:CRD42013004420. Available at http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013004420. Accessed October 27, 2017.
61. Higuchi, T, Hong, JP, Jung, HY, Watanabe, Y, Kunitomi, T, Kamijima, K. Paroxetine controlled‐release formulation in the treatment of major depressive disorder: a randomized, double‐blind, placebo‐controlled study in Japan and Korea. Psychiatry Clin Neurosci 2011;65:655–663.
63. Garattini, S, Jakobsen, JC, Wetterslev, J et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. Eur J Intern Med 2016;32:13–21.
65. Ball, WA, Snavely, DB, Hargreaves, RJ, Szegedi, A, Lines, C, Reines, SA. Addition of an Nk1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Hum Psychopharmacol 2014;29:568–577.
68. Loo, H, Hale, A, D’haenen, H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239–247.
69. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark. Review Manager (RevMan) 5.3., 2014.
70. StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC, 2017.
74. Østergaard, SD. Do not blame the SSRIs: blame the Hamilton Depression Rating Scale. Acta Neuropsychiatr 2017;1–3.
75. Hooper, CL, Bakish, D. An examination of the sensitivity of the six-item Hamilton Rating Scale for Depression in a sample of patients suffering from major depressive disorder. J Psychiatry Neurosci 2000;25:178–184.
76. O’Sullivan, RL, Fava, M, Agustin, C, Baer, L, Rosenbaum, J. Sensitivity of the six‐item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1997;95:379–384.
77. Gluud, C, Brok, J, Gong, Y, Koretz, RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007;46:734–742.
78. Ragland, DR. Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology 1992;3:434–440.
79. Dawson, NV, Weiss, R. Dichotomizing continuous variables in statistical analysis. A practice to avoid. Med Decis Making 2012;32:225–226.
80. Altman, DG, Royston, P. The cost of dichotomising continuous variables. BMJ. 2006;332:1080.
81. Kirsch, I, Moncrieff, J. Clinical trials and the response rate illusion. Contemp Clin Trials 2007;28:348–351.
82. Fabre, LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry, 1992;53(Suppl):40–43.
83. Nørby, ET. Svar til spørgsmål nr. 1056 (Alm. del) til sundhedsministeren fra Folketingets Sundheds- og Ældreudvalg den 18. juli 2017. Sagsnr.: 1705343. Dok. nr.: 416878. [Answer to question no. 1056 (general part) to the Minister of Health from the Committee on Health and Elderly the 28th of July, 2017. Case no. 1705343. Dokument no. 416878. Available at http://www.ft.dk/samling/20161/almdel/suu/spm/1056/index.htm. Accessed October 27, 2017.